TJ252B - Benzothiophene benzofuran indolethiazepinone oxazepinone and diazepinone derivatives pharmaceutical composition having activity which is inhibited the cellular adhesion or hiv method of inhibition of the adhesion leukocytes to endothelial cells at treatment of the illnesses caused by it method of treatment of the mammalian infected hiv - Google Patents

Benzothiophene benzofuran indolethiazepinone oxazepinone and diazepinone derivatives pharmaceutical composition having activity which is inhibited the cellular adhesion or hiv method of inhibition of the adhesion leukocytes to endothelial cells at treatment of the illnesses caused by it method of treatment of the mammalian infected hiv

Info

Publication number
TJ252B
TJ252B TJ96000405A TJ96000405A TJ252B TJ 252 B TJ252 B TJ 252B TJ 96000405 A TJ96000405 A TJ 96000405A TJ 96000405 A TJ96000405 A TJ 96000405A TJ 252 B TJ252 B TJ 252B
Authority
TJ
Tajikistan
Prior art keywords
treatment
hiv
adhesion
benzothiophene
benzofuran
Prior art date
Application number
TJ96000405A
Other languages
English (en)
Inventor
Diane Harris Boschelli
David Thomas Connor
James Bernard Kramer
Paul Charles Unangst
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TJ252B publication Critical patent/TJ252B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
TJ96000405A 1994-03-07 1995-01-30 Benzothiophene benzofuran indolethiazepinone oxazepinone and diazepinone derivatives pharmaceutical composition having activity which is inhibited the cellular adhesion or hiv method of inhibition of the adhesion leukocytes to endothelial cells at treatment of the illnesses caused by it method of treatment of the mammalian infected hiv TJ252B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20733094A 1994-03-07 1994-03-07
PCT/US1995/001275 WO1995024408A1 (en) 1994-03-07 1995-01-30 Benzothiophene, benzofuran and indolethiazepinones, oxazepinones and diazepinones as inhibitors of cell adhesion and as inhibitors of hiv

Publications (1)

Publication Number Publication Date
TJ252B true TJ252B (en) 1999-12-23

Family

ID=22770077

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ96000405A TJ252B (en) 1994-03-07 1995-01-30 Benzothiophene benzofuran indolethiazepinone oxazepinone and diazepinone derivatives pharmaceutical composition having activity which is inhibited the cellular adhesion or hiv method of inhibition of the adhesion leukocytes to endothelial cells at treatment of the illnesses caused by it method of treatment of the mammalian infected hiv

Country Status (28)

Country Link
US (2) US5489586A (ro)
EP (1) EP0749434B1 (ro)
JP (1) JPH09509961A (ro)
KR (2) KR100338017B1 (ro)
AT (1) ATE187728T1 (ro)
AU (1) AU688466B2 (ro)
BG (1) BG62698B1 (ro)
CA (1) CA2181354A1 (ro)
CZ (1) CZ292009B6 (ro)
DE (1) DE69513961T2 (ro)
DK (1) DK0749434T3 (ro)
ES (1) ES2141922T3 (ro)
FI (1) FI963462A0 (ro)
GE (1) GEP19991835B (ro)
GR (1) GR3032861T3 (ro)
HU (1) HUT77403A (ro)
MD (1) MD1688G2 (ro)
NO (1) NO313384B1 (ro)
NZ (1) NZ279737A (ro)
PH (1) PH31163A (ro)
PL (1) PL180457B1 (ro)
RO (1) RO117919B1 (ro)
RU (1) RU2144033C1 (ro)
SK (1) SK282962B6 (ro)
TJ (1) TJ252B (ro)
UA (1) UA45967C2 (ro)
WO (1) WO1995024408A1 (ro)
ZA (1) ZA951844B (ro)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612330A (en) * 1994-03-07 1997-03-18 Warner-Lambert Company Methods for inhibiting and controlling viral growth
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
ATE330955T1 (de) 1998-04-28 2006-07-15 Elbion Ag Indolderivate und deren verwendung als inhibitoren der phosphodiesterase 4.
US7015212B1 (en) 1999-05-12 2006-03-21 The United States Of America As Represented By The Department Of Health And Human Services Thiazepine inhibitors of HIV-1 integrase
DE19944829A1 (de) * 1999-09-18 2001-06-13 Kundo Systemtechnik Gmbh Ultraschall-Durchflußmesser
AU2001281142A1 (en) * 2000-08-16 2002-02-25 Japan Tobacco Inc. Diazepinones as antiviral agents
JP2005089298A (ja) * 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
AU2003239150A1 (en) * 2002-04-23 2003-11-10 Aventis Pharmaceuticals Inc. 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo
GB0217920D0 (en) * 2002-04-23 2002-09-11 Aventis Pharm Prod Inc Interleukin-4 Gene Expression inhibitors
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
EP1615885A1 (en) * 2003-04-15 2006-01-18 Warner-Lambert Company LLC B -fused bicyclic proline derivatives and their use for treating arthritic conditions
CN1238357C (zh) * 2003-10-22 2006-01-25 中国科学院昆明植物研究所 炭球菌素及其制备方法和应用
US20050203081A1 (en) * 2004-02-25 2005-09-15 Jinbo Lee Inhibitors of protein tyrosine phosphatase 1B
DE602005023360D1 (de) 2004-09-17 2010-10-14 Idenix Pharmaceuticals Inc Phosphoindole als HIV-Inhibitoren
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
JP2009062278A (ja) * 2005-12-29 2009-03-26 Nippon Chemiphar Co Ltd Ｐ２ｘ４受容体拮抗剤
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
NZ575831A (en) 2006-09-29 2011-12-22 Idenix Pharmaceuticals Inc Enantiomerically pure phosphoindoles as hiv inhibitors
EP2640729B1 (en) * 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibitors of hiv replication
RU2506082C2 (ru) * 2011-05-24 2014-02-10 Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова Антигипотоническое средство
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
CN118974057A (zh) * 2022-02-07 2024-11-15 里帕里安制药股份有限公司 Klf2诱导剂及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013641A (en) * 1975-10-08 1977-03-22 Xerox Corporation Indolobenzoxazepines
AU5883794A (en) * 1993-01-20 1994-08-15 A. Menarini Industrie Farmaceutiche Riunite S.R.L. Diazepin derivatives and antiviral compositions

Also Published As

Publication number Publication date
EP0749434B1 (en) 1999-12-15
MD1688G2 (ro) 2002-01-31
ES2141922T3 (es) 2000-04-01
CZ292009B6 (cs) 2003-07-16
SK282962B6 (sk) 2003-01-09
UA45967C2 (uk) 2002-05-15
GEP19991835B (en) 1999-11-05
US5565446A (en) 1996-10-15
FI963462A7 (fi) 1996-09-04
US5489586A (en) 1996-02-06
PL316197A1 (en) 1996-12-23
DE69513961D1 (de) 2000-01-20
MD1688F2 (ro) 2001-06-30
RU2144033C1 (ru) 2000-01-10
EP0749434A1 (en) 1996-12-27
MD960230A (ro) 1997-10-31
DE69513961T2 (de) 2000-06-29
NO963744L (no) 1996-09-06
CZ259796A3 (en) 1997-06-11
HUT77403A (hu) 1998-04-28
RO117919B1 (ro) 2002-09-30
SK114196A3 (en) 1997-03-05
JPH09509961A (ja) 1997-10-07
AU1697395A (en) 1995-09-25
FI963462L (fi) 1996-09-04
BG100829A (bg) 1997-10-31
ZA951844B (en) 1995-12-12
BG62698B1 (bg) 2000-05-31
FI963462A0 (fi) 1996-09-04
KR100338017B1 (ko) 2002-11-23
NO963744D0 (no) 1996-09-06
WO1995024408A1 (en) 1995-09-14
GR3032861T3 (en) 2000-07-31
NO313384B1 (no) 2002-09-23
NZ279737A (en) 1997-07-27
KR100325881B1 (ko) 2002-03-20
PH31163A (en) 1998-03-20
CA2181354A1 (en) 1995-09-14
DK0749434T3 (da) 2000-05-29
AU688466B2 (en) 1998-03-12
HU9602451D0 (en) 1996-11-28
ATE187728T1 (de) 2000-01-15
PL180457B1 (pl) 2001-02-28

Similar Documents

Publication Publication Date Title
TJ252B (en) Benzothiophene benzofuran indolethiazepinone oxazepinone and diazepinone derivatives pharmaceutical composition having activity which is inhibited the cellular adhesion or hiv method of inhibition of the adhesion leukocytes to endothelial cells at treatment of the illnesses caused by it method of treatment of the mammalian infected hiv
Schuppan et al. Hepatic fibrosis: from bench to bedside
UA43391C2 (uk) Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію
GEP20084497B (en) Hiv protease inhibitors
DE69324151D1 (de) Inhibitoren des arginin-ketoamid-enzyms
LV10054A (lv) Pretvirusu antibakterials savienojums un lietosanas metode
ATE202383T1 (de) Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten
MXPA04012965A (es) Inhibidores virales.
EP0675899A4 (en) NEW INHIBITORS FROM FACTOR Xa.
PT916666E (pt) 3-alquiloxi- ariloxi- ou arilalquiloxi-benzo¬b|tiofeno-2-carboxamidas como inibidores de adesao celular
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
MX9602996A (es) Benzotiofeno, benzofurano e indolo-tiazepinones, oxazepinones y diazepinones como inhibidores de la adhesion celular y como inhibidores de vih.
ATE210445T1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 7 infektionen
TW200517112A (en) Compounds and pharmaceutical composition for inhibiting HIV protease
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof
MY106984A (en) Antiviral or antibacterial composition and method of use.